Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;111(4):367-379.
doi: 10.1007/s00223-022-01005-8. Epub 2022 Jul 20.

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases

Ariadne Bosman #  1 , Andrea Palermo #  2 , Julien Vanderhulst  3 , Suzanne M Jan De Beur  4 , Seiji Fukumoto  5 , Salvatore Minisola  6 , Weibo Xia  7 , Jean-Jacques Body  3 , M Carola Zillikens  8
Affiliations
Review

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases

Ariadne Bosman et al. Calcif Tissue Int. 2022 Oct.

Abstract

Tumor-induced osteomalacia (TIO) is a rare and largely underdiagnosed paraneoplastic condition. Previous reviews often reported incomplete data on clinical aspects, diagnosis or prognosis. The aim of this study was to present a systematic clinical review of all published cases of TIO. A search was conducted in Pubmed, Embase, Web of Science from inception until April 23rd, 2020. We selected case reports and case series of patients diagnosed with TIO, with information on tumor localization and serum phosphate concentration. Two reviewers independently extracted data on biochemical and clinical characteristics including bone involvement, tumor localization and treatment. 468 articles with 895 unique TIO cases were included. Median age was 46 years (range 9 months-90 years) and 58.3% were males. Hypophosphatemia and inappropriately low or normal 1,25-dihydroxyvitamin D levels, characteristic for TIO, were present in 98% of cases. Median tumor size was 2.7 cm (range 0.5 to 25.0 cm). Serum fibroblast growth factor 23 was related to tumor size (r = 0.344, P < 0.001). In 32% of the cases the tumor was detected by physical examination. Data on bone phenotype confirmed skeletal involvement: 62% of cases with BMD data had a T-score of the lumbar spine ≤ - 2.5 (n = 61/99) and a fracture was reported in at least 39% of all cases (n = 346/895). Diagnostic delay was longer than 2 years in more than 80% of cases. 10% were reported to be malignant at histology. In conclusion, TIO is a debilitating disease characterized by a long diagnostic delay leading to metabolic disturbances and skeletal impairment. Increasing awareness of TIO should decrease its diagnostic delay and the clinical consequences.

Keywords: FGF23; Fracture; Hypophosphatemia; Osteomalacia; Rickets; Tumor-induced osteomalacia.

PubMed Disclaimer

Conflict of interest statement

AB is supported by a Grant from Health ~ Holland (PhosphoNorm; LSHM18029). AP, JV WX, and JB declare they have no financial interests. SB received grants from Ultragenyx and consulting fees from Ultragenyx, Amgen and Inozyme. SB serves on the Data Safety Monitory Board of NIDCR (NIH) and NIDDK (FIT4KIDS); on the advisory board of Ultragenyx, Amgen and Inozyme; and in the scientific advisory board of the XLH network. SF received lecture fees from Kyowa Kirin, and is president of the Japanese Society for Bone and Mineral Research (JSBMR). SM served as speaker for Abiogen, Bruno Farmaceutici, Diasorin, Kyowa Kirin, UCB. He also served in advisory boards of Eli Lilly, Kyowa Kirin, UCB. MCZ reports that her institution has received a research grant from Kyowa Kirin and she is an unpaid board member of the steering committee of the Kyowa Kirin International XLH registry.

Figures

Fig. 1
Fig. 1
Flow diagram of the search
Fig. 2
Fig. 2
Distribution of serum phosphate, 1.25 (OH)2 D levels and the times of the upper limit of normal FGF-23 among adults with TIO. Histograms showing the distribution of serum phosphate in mmol/L (A), serum 1.25(OH)2 Vitamine D in pmol/L (B) and the times of the upper limit of normal of FGF-23 (C). Normal range for serum phosphate: 0.74–1.52 mmol/L. Normal range for serum 1.25(OH)2 Vitamin D: 50–155 pmol/L. FGF-23 Fibroblast growth factor 23, ULN upper limit of normal
Fig. 3
Fig. 3
Localization of the tumor
See this image and copyright information in PMC

References

    1. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004;65:1–14. doi: 10.1111/j.1523-1755.2004.00355.x. - DOI - PubMed
    1. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR, Kumar R. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330:1645–1649. doi: 10.1056/NEJM199406093302304. - DOI - PubMed
    1. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500–6505. doi: 10.1073/pnas.101545198. - DOI - PMC - PubMed
    1. Ryan EA, Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med. 1984;77:501–512. doi: 10.1016/0002-9343(84)90112-8. - DOI - PubMed
    1. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442–1454. doi: 10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q. - DOI - PubMed

Substances

Supplementary concepts

LinkOut - more resources